Onureg 200 mg film coated tablets

DRUG3 trials

Sponsors

LYSARC, Martin-Luther-Universitaet Halle-Wittenberg, French Innovative Leukemia Organization

Conditions

Myeloproliferative neoplasm in accelerated phase (MPN-AP)Patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutationRELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMASin complete remission after intensive chemotherapy.

Phase 1

Fedratinib in Combination with CC-486, a Hypomethylating Agent, in Patients with Accelerated Phase Myelofibrosis - FAMy

Active, not recruitingCTIS2024-519227-22-00

Martin-Luther-Universitaet Halle-WittenbergMyeloproliferative neoplasm in accelerated phase (MPN-AP)

Start: 2022-11-03Target: 44Updated: 2025-11-20

PLATFORM - A PLATFORM TRIAL, EVALUATING NEW DRUGS OR COMBINATION IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS

RecruitingCTIS2024-514954-63-00

LYSARCRELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS

Start: 2025-08-20Target: 80Updated: 2025-12-03

Phase 2

FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onureg®) in patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. A study of the French AML Intergroup.

Not yet recruitingCTIS2025-521322-14-00

French Innovative Leukemia Organizationin complete remission after intensive chemotherapy., Patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation

Target: 60Updated: 2025-11-17